Good MorningThe S&P 500 advanced Thursday, cheering the Fed's decision to cut rates by fifty basis points. The question is if the market can hold the gains, and the answer is, at best, maybe. While the Fed's decision indicates inflation has cooled, the aggressive pace and outlook raise doubt about current economic health. With labor data softening, the US economy may be on the brink of recession now, and it is too late for the FOMC to stop it.
Risk aside, assuming the Fed has threaded the needle to its soft landing, volatility will likely remain elevated because of sector rotation. With the Fed reducing rates and easing the economic headwind, two years of the S&P 500 winding up on higher rates and the AI bubble are about to unwind in favor of small and mid-cap stocks.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | |
Investors cautious about the Federal Reserve's September rate cut—confirmed at its mid-month meeting to be a full 50 basis points—and skeptical about the strength of the dollar have flocked to gold, sending the most famous safe haven commodity soaring to record highs. But there is only... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Healthcare | |
Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for shor... Read the Full Story |
|
Markets | |
With the Federal Open Market Committee (FOMC) cutting interest rates by a larger-than-expected 50 basis points in its September meeting, businesses throughout the country will be able to take out loans more cheaply. One intended goal of a rate cut like this is to foster increased profitability thr... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Since powering to several all-time highs in June and July, shares of Microsoft Corp (NASDAQ: MSFT) have been struggling to regain momentum. Equities, in general, had a solid first half of the year, but interest rate jitters and a general softening of sentiment towards tech brought about some volat... Read the Full Story |
|
Communication Services | |
Alphabet (NASDAQ: GOOGL), the tech giant behind Google, has seen a recovery in recent days, with shares climbing nearly 6% over the past five days. However, despite this recent bounce, the stock remains down nearly 17% from its 52-week high, weighed down by market rotation and ongoing antitrust ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Communication Services | |
Verizon's (NYSE: VZ) stock price is amid a technical reversal and will likely advance 45% or more. After years of sluggish growth and uncertainty driven by the pandemic, the 5G industry is set to boom in 2025. The forecast is for widening us driven by increased network availability and use cases f... Read the Full Story |
|
Markets | |
The FOMC gave the market what it wanted: a 50-basis point interest rate cut and an outlook for aggressive cuts to continue through the end of next year. As good as the news is, the outcome is that there is as much uncertainty about the future as there has been all year and a rising risk of heighte... Read the Full Story |
|
Consumer Discretionary | |
When there is uncertainty in the stock market, investors should pay more attention than usual to Wall Street analyst ratings and price target adjustments. These analysts rarely stick their necks out and risk their reputations – and careers when they make new calls during high-volatility even... Read the Full Story |
|
Consumer Staples | |
General Mills (NYSE: GIS) can provide a hedge if volatility continues to plague the S&P 500. The company is amid a business transformation telegraphed in its price action, which is set up for a significant reversal after more than a year of lackluster performance.
The transformation includ... Read the Full Story |
|
Healthcare | |
Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.
... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. | | View Today's Stock Pick |
|
